Patenting Antibody and Cell Therapies – What to Do and What Not to Do

In Webinars

28 September, 2020

Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.

You may also be interested in:

CJEU clarifies protected designations of origin in Danish Feta case

A recent judgment from the Court of Justice of the European Union has clarified the extent of protection for

Read more...

New Guidelines on Pricing affect Marketing and Promotions in Denmark

On May 28, 2022, the Danish consumer ombudsman published long-awaited Guidelines on price marketing. The Guidelines are identical to

Read more...

Key Takeaways: CNIPA notice on malicious trademark registrations

On 29 March 2022 the China National Intellectual Property Administration (CNIPA) released the “Notice on Continuing to Severely Crack

Read more...

Mobile Sliding Menu